Does the media refer more to LGND or ADMA?

In the previous week, ADMA Biologics had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 25 mentions for ADMA Biologics and 18 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.49 beat ADMA Biologics' score of 0.46 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ADMA Biologics 3 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LGND or ANIP?

In the previous week, ANI Pharmaceuticals had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 25 mentions for ANI Pharmaceuticals and 18 mentions for Ligand Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.50 beat Ligand Pharmaceuticals' score of 0.49 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ANI Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, LGND or INCY?

Incyte has higher revenue and earnings than Ligand Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ligand Pharmaceuticals $268.09M 23.44 $124.45M $2.24 140.25 Incyte $5.14B 4.77 $1.29B $1.88 63.99

Does the media favor LGND or INCY?

In the previous week, Incyte had 9 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 27 mentions for Incyte and 18 mentions for Ligand Pharmaceuticals. Incyte's average media sentiment score of 0.62 beat Ligand Pharmaceuticals' score of 0.49 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Incyte 11 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to LGND or UTHR?

In the previous week, United Therapeutics had 34 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 52 mentions for United Therapeutics and 18 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.49 beat United Therapeutics' score of 0.48 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral United Therapeutics 23 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BNTX or LGND?

In the previous week, BioNTech had 6 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 24 mentions for BioNTech and 18 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.49 beat BioNTech's score of 0.22 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Ligand Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Ligand Pharmaceuticals (LGND) Competitors

$316.83 +2.67 (+0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$317.20 +0.37 (+0.12%)

As of 04:15 PM Eastern

Compare

LGND vs. ADMA, ANIP, INCY, UTHR, and BNTX

Should you buy Ligand Pharmaceuticals stock or one of its competitors? Ligand Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Incyte (INCY), United Therapeutics (UTHR), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Ligand Pharmaceuticals currently has a consensus target price of $354.75, indicating a potential upside of 12.92%. ADMA Biologics has a consensus target price of $17.50, indicating a potential upside of 38.12%. Given ADMA Biologics' higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

In the previous week, ADMA Biologics had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 25 mentions for ADMA Biologics and 18 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.49 beat ADMA Biologics' score of 0.46 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ADMA Biologics	3 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a net margin of 35.14% compared to Ligand Pharmaceuticals' net margin of 20.27%. ADMA Biologics' return on equity of 42.56% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	20.27%	5.22%	2.74%
ADMA Biologics	35.14%	42.56%	26.96%

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.44	$124.45M	$2.24	140.25
ADMA Biologics	$519.15M	5.47	$146.93M	$0.77	16.45

Summary

Ligand Pharmaceuticals beats ADMA Biologics on 9 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Ligand Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.44	$124.45M	$2.24	140.25
ANI Pharmaceuticals	$883.37M	1.85	$78.34M	$5.02	14.19

Ligand Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

In the previous week, ANI Pharmaceuticals had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 25 mentions for ANI Pharmaceuticals and 18 mentions for Ligand Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.50 beat Ligand Pharmaceuticals' score of 0.49 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals has a net margin of 20.27% compared to ANI Pharmaceuticals' net margin of 11.22%. ANI Pharmaceuticals' return on equity of 28.34% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	20.27%	5.22%	2.74%
ANI Pharmaceuticals	11.22%	28.34%	11.18%

Ligand Pharmaceuticals currently has a consensus price target of $354.75, indicating a potential upside of 12.92%. ANI Pharmaceuticals has a consensus price target of $100.00, indicating a potential upside of 40.35%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Ligand Pharmaceuticals and ANI Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Incyte?

Ligand Pharmaceuticals (NASDAQ:LGND) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Incyte has higher revenue and earnings than Ligand Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.44	$124.45M	$2.24	140.25
Incyte	$5.14B	4.77	$1.29B	$1.88	63.99

Ligand Pharmaceuticals presently has a consensus target price of $354.75, suggesting a potential upside of 12.92%. Incyte has a consensus target price of $132.86, suggesting a potential upside of 10.44%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Ligand Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Incyte	1 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.40

Ligand Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Incyte has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

In the previous week, Incyte had 9 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 27 mentions for Incyte and 18 mentions for Ligand Pharmaceuticals. Incyte's average media sentiment score of 0.62 beat Ligand Pharmaceuticals' score of 0.49 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Incyte	11 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 20.27% compared to Incyte's net margin of 6.71%. Incyte's return on equity of 7.92% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	20.27%	5.22%	2.74%
Incyte	6.71%	7.92%	6.12%

Summary

Incyte beats Ligand Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to United Therapeutics?

Ligand Pharmaceuticals (NASDAQ:LGND) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Ligand Pharmaceuticals presently has a consensus price target of $354.75, suggesting a potential upside of 12.92%. United Therapeutics has a consensus price target of $676.40, suggesting a potential upside of 14.91%. Given United Therapeutics' higher probable upside, analysts clearly believe United Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
United Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, United Therapeutics had 34 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 52 mentions for United Therapeutics and 18 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.49 beat United Therapeutics' score of 0.48 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
United Therapeutics	23 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

United Therapeutics has a net margin of 38.61% compared to Ligand Pharmaceuticals' net margin of 20.27%. United Therapeutics' return on equity of 19.18% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	20.27%	5.22%	2.74%
United Therapeutics	38.61%	19.18%	17.07%

Ligand Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.44	$124.45M	$2.24	140.25
United Therapeutics	$3.19B	7.86	$1.33B	$26.50	22.21

Summary

United Therapeutics beats Ligand Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 20.27% compared to BioNTech's net margin of -61.39%. Ligand Pharmaceuticals' return on equity of 5.22% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-61.39%	-4.51%	-3.96%
Ligand Pharmaceuticals	20.27%	5.22%	2.74%

BioNTech presently has a consensus price target of $122.27, suggesting a potential upside of 40.20%. Ligand Pharmaceuticals has a consensus price target of $354.75, suggesting a potential upside of 12.92%. Given BioNTech's higher probable upside, equities research analysts clearly believe BioNTech is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Ligand Pharmaceuticals has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.79	-$1.29B	-$6.85	N/A
Ligand Pharmaceuticals	$268.09M	23.44	$124.45M	$2.24	140.25

BioNTech has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

In the previous week, BioNTech had 6 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 24 mentions for BioNTech and 18 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.49 beat BioNTech's score of 0.22 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Ligand Pharmaceuticals beats BioNTech on 10 of the 17 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGND vs. The Competition

Export

Metric	Ligand Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.34B	$4.17B	$7.89B	$12.22B
Dividend Yield	N/A	3.64%	2.47%	4.44%
P/E Ratio	141.44	25.46	35.35	30.86
Price / Sales	23.64	16.44	8.45	5.83
Price / Cash	40.01	26.87	22.22	22.66
Price / Book	6.59	4.21	4.43	3.79
Net Income	$124.45M	-$22.76M	$3.50B	$390.16M
7 Day Performance	0.22%	-1.04%	-0.95%	-1.10%
1 Month Performance	4.98%	-6.74%	-4.05%	-6.18%
1 Year Performance	51.81%	1.86%	2.09%	-5.73%

Ligand Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGND Ligand Pharmaceuticals	2.9451 of 5 stars	$316.83 +0.8%	$355.38 +12.2%	+50.1%	$6.34B	$268.09M	141.44	47	Analyst Forecast
ADMA ADMA Biologics	3.8845 of 5 stars	$12.73 -3.6%	$17.50 +37.5%	-13.9%	$2.85B	$510.17M	16.53	647	Earnings Report
ANIP ANI Pharmaceuticals	3.6364 of 5 stars	$67.41 -3.2%	$100.00 +48.3%	-19.9%	$1.55B	$978.38M	14.53	970	Earnings Report
INCY Incyte	2.864 of 5 stars	$119.65 +1.4%	$132.86 +11.0%	+13.5%	$24.39B	$5.14B	63.64	2,844	Insider Trade
UTHR United Therapeutics	4.4863 of 5 stars	$562.02 -0.7%	$676.40 +20.4%	+29.7%	$24.11B	$3.18B	21.21	1,400	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGND) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, INCY, UTHR, and BNTX

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Ligand Pharmaceuticals compare to Incyte?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Summary

How does Ligand Pharmaceuticals compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, INCY, UTHR, and BNTX

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Do analysts recommend LGND or ADMA?

Do insiders and institutionals believe in LGND or ADMA?

Which has more volatility & risk, LGND or ADMA?

Does the media refer more to LGND or ADMA?

Is LGND or ADMA more profitable?

Which has higher earnings and valuation, LGND or ADMA?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Which has better valuation and earnings, LGND or ANIP?

Which has more risk and volatility, LGND or ANIP?

Does the media favor LGND or ANIP?

Do institutionals & insiders have more ownership in LGND or ANIP?

Is LGND or ANIP more profitable?

Do analysts prefer LGND or ANIP?

Summary

How does Ligand Pharmaceuticals compare to Incyte?

Do institutionals and insiders have more ownership in LGND or INCY?

Which has higher valuation & earnings, LGND or INCY?

Do analysts prefer LGND or INCY?

Which has more risk & volatility, LGND or INCY?

Does the media favor LGND or INCY?

Is LGND or INCY more profitable?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Do analysts rate LGND or UTHR?

Do insiders and institutionals have more ownership in LGND or UTHR?

Does the media refer more to LGND or UTHR?

Is LGND or UTHR more profitable?

Which has more volatility and risk, LGND or UTHR?

Which has stronger earnings & valuation, LGND or UTHR?

Summary

How does Ligand Pharmaceuticals compare to BioNTech?

Do institutionals and insiders have more ownership in BNTX or LGND?

Is BNTX or LGND more profitable?

Do analysts recommend BNTX or LGND?

Which has higher earnings and valuation, BNTX or LGND?

Which has more risk and volatility, BNTX or LGND?

Does the media prefer BNTX or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools